Abstracts
PNL26 TREATMENT SATISFACTION AND PRINCIPAL CAUSES OF TERMINATION OF DRUG TREATMENT OF PARKINSON'S DISEASE IN RUSSIA
Chikina ES, Gusev EI Russian State Medical University, Moscow, Moscow, Russia OBJECTIVES: To establish and analyse treatment satisfaction and principal causes which result in termination of drug treatment of Parkinson's Disease (PD) in Russia. METHODS: The retrospective analysis was carried out for treatment which patients received. In the analysis, 241 patients with PD (male: 127, female: 114; mean age: 66.1 ± 7.5 years, duration of disease: 5.2 ± 3.2 years) have been included. RESULTS: Majority of patients received two or three drugs; 160 patients accepted levodopa (mean dose: 612.0 ± 327.7 mg daily); 105 patients accepted anticholinergics such as trihexyphenidyl (mean dose: 5.0 ± 2.0 mg); 83 patients accepted amantadine (mean dose: 253.9 ± 72.1 mg); 41 patients accepted dopamine agonist such as pramipexole (mean dose: 2.4 ± 1.0 mg); and 35 patients accepted selegiline (mean dose: 9.1 ± 3.2 mg). Adverse events resulted in termination of treatment more often for anticholinergics (n = 32), less often for levodopa (n = 8), amantadine (n = 5) and pramipexole (n = 4). Insufficient efficacy was the most often cause of end in treatment by trihexyphenidyl (n = 21), selegiline (n = 17), amantadine (n = 15), and rare reason of end of treatment by levodopa (n = 3), pramipexole (n = 2). High cost of drugs was the most often reason of pramipexole (n = 27) cancellation and only one case led to cancellation of levodopa. In other cases, patients were satisfied with the treatment. In Russia, mean daily dose of levodopa costs about US$0.9, pramipexole-US$3.96, selegiline-US$0.88, amantadine-US$0.05 and trihexyphenidyl-US$0.02. CONCLUSIONS: Principal causes of the termination of drug treatment of PD were adverse events, insufficient efficiency, and high cost. Reduction of cost of treatment of dopamine agonists such as pramipexole could lead to increase in number of PD patients who would continue to get treated in Russia.
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PNL27 PREVALENCE OF INSOMNIA AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN A LARGE DATABASE
Vallarino C, Rajagopalan R, Mini L Takeda Pharmaceuticals North America Inc, Lincolnshire, IL, USA OBJECTIVES: This retrospective study quantifies the prevalence of insomnia among patients with chronic obstructive pulmonary disease (COPD) from a large outpatient database. COPD is an umbrella term for the lung disease category associated with airflow obstruction, which includes emphysema, chronic bronchitis, and chronic asthma, either alone or in combination. METHODS: Data from April, 1996 to September, 2003 on patients with a diagnosis of COPD (ICD-9 codes 491.2, 492.0, 492.8, 493.2, and 496) were extracted from the GE Medical Systems database-a large, outpatient, multipractice electronic database system with input from over 2000 practicing physicians in 26 US states. The insomnia cohort was defined as patients having either a diagnosis consistent with insomnia (ICD-9 codes 307.4x [x = 1-2, 9] and 780.5x [x = 0, 2] or a prescription for insomnia medication. Demographic characteristics, comorbid conditions, and concomitant medications were evaluated. RESULTS: A total of 5,777 (21.4%) of 27,052 patients in the COPD cohort were identified as having a diagnosis and/or being treated for insomnia, compared with 7.2% of the non-COPD patients. CONCLUSIONS: This exploratory analysis revealed that patients with COPD in this large outpatient database were diagnosed with and/or treated for insomnia almost three times as frequently as those patients not having a diagnosis of COPD. These data suggest that insomnia is a common and clinically important comorbidity associated with COPD. The nature of this association should be further investigated with a welldesigned prospective study, and treatments for insomnia related to COPD need to be examined in greater detail.
